In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Biodexa Pharmaceuticals Plc ADR’s stock clocked out at $1.15, up 6.48% from its previous closing price of $1.08. In other words, the price has increased by $6.48 from its previous closing price. On the day, 1.16 million shares were traded.
Ratios:
To gain a deeper understanding of BDRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.75 and its Current Ratio is at 1.75. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on February 08, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Stock Price History:
Over the past 52 weeks, BDRX has reached a high of $41.50, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -18.00%, while the 200-Day Moving Average is calculated to be -76.53%.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.04 and -$0.04 for the fiscal current year, implying an average EPS of -$0.04. EPS for the following year is -$0.01, with 1.0 analysts recommending between -$0.01 and -$0.01.
